In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Medically reviewed by Corinne Savides Happel, MD The immune system is responsible for protecting the body from disease. And ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Johnson & Johnson today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment ...

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...

This autoimmune disease is tricky to diagnose because it mimics so many other illnesses. If you have more than four of any of ...

For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Apheresis Overview Apheresis is a medical technology used to separate various constituents of the blood, in which the remaining components of the blood are returned to the patient after extraction of ...

China NMPA approves Astellas Pharma’s Padcev in combination with Keytruda to treat advanced bladder cancer: Tokyo Thursday, January 9, 2025, 09:00 Hrs [IST] Astellas Pharma Inc.